Ticker Scorecard - KNSA Basics Company: Kiniksa Pharmaceuticals, Ltd. IPO Date: May 21, 2018 Sector: Healthcare Industry: Biotech Market Cap: $1.44B Activated in VL: True Average Daily Range Avg Daily Range: $0.45 | 2.80% Avg Daily Range (30 D): $0.26 | 1.30% Avg Daily Range (90 D): $0.37 | 1.62% Institutional Daily Volume Avg Daily Volume: .26M Avg Daily Volume (30 D): .27M Avg Daily Volume (90 D): .26M Trade Size Avg Trade Size (Sh.): 75 Avg Trade Size (Sh.) (30 D): 50 Avg Trade Size (Sh.) (90 D): 47 Institutional Trades Total Inst.Trades: 1,177 Avg Inst. Trade: $1.51M Avg Inst. Trade (30 D): $1.99M Avg Inst. Trade (90 D): $2.02M Avg Inst. Trade Volume: .09M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $1.18M Avg Closing Trade (90 D): $1.86M Avg Closing Volume: 85.03K     News Jan 14, 2025 @ 6:00 PM Evolving Landscape of Cardiology Segment: Key Mark... Source: Delveinsight Nov 4, 2024 @ 6:00 PM Urticaria Clinical Trial Pipeline Accelerates: 20+... Source: Delveinsight Jun 17, 2024 @ 12:30 PM Kiniksa Pharmaceuticals Sponsors American Heart As... Source: Kiniksa Pharmaceuticals, Ltd. Jun 4, 2024 @ 8:01 PM Kiniksa Pharmaceuticals to Present at Goldman Sach... Source: Kiniksa Pharmaceuticals, Ltd. May 7, 2024 @ 8:01 PM Kiniksa Pharmaceuticals to Present at Bank of Amer... Source: Kiniksa Pharmaceuticals, Ltd. Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.12 $-.18 $-.06 Diluted EPS $-.12 $-.18 $-.06 Revenue $ 384.1M $ 112.21M $ 108.63M Gross Profit $ $ 92.11M $ 96.31M Net Income / Loss $ -9.07M $ -12.69M $ -3.91M Operating Income / Loss $ -26.24M $ -9.66M $ -.12M Cost of Revenue $ $ 20.11M $ 12.32M Net Cash Flow $ -20.45M $ -1.9M $ -41.81M PE Ratio